

08 September 2026

BSF Enterprise PLC
("BSF" or the "Company")

Publication of Prospectus to Support Historic Warrants and Convertible Securities, Exercise of Warrants and Total Voting Rights

BSF Enterprise PLC (LSE: BSFA), (OTCQB: BSFAF), the biotechnology company focused on developing tissue engineering, lab-grown materials and bioactive solutions, is pleased to announce that the Financial Conduct Authority has approved the Company's prospectus dated 08 September 2026 (the "Prospectus").

The Prospectus provides a formal, long-term regulatory framework to facilitate the potential exercise of existing warrants and convertible instruments over the coming 12 months, ensuring orderly headroom for the Company's ongoing commercial scale-up. The Prospectus has been prepared in connection with the proposed admission to the Equity Shares (Transition) Category of the Official List of the Financial Conduct Authority and to trading on the Main Market of the London Stock Exchange of new Ordinary Shares which may be issued pursuant to the exercise of certain existing warrants and/or the conversion of existing convertible securities, as further described in the Prospectus.

Exercise of Warrants and Admission

The Company has received a notice of exercise in respect of 100,000 warrants at an exercise price of 1 penny per Ordinary Share.

Accordingly, the Company will issue 100,000 new ordinary shares of £0.01 each in the capital of the Company (the "New Ordinary Shares").

Application has been made for the New Ordinary Shares to be admitted to the Equity Shares (Transition) Category of the Official List and to trading on the Main Market of the London Stock Exchange.

It is expected that Admission will become effective and dealings in the New Ordinary Shares will commence at 8.00 a.m. on 11 September 2026.

The New Ordinary Shares will, on Admission, rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid following their issue.

Total Voting Rights

Following Admission, the Company's issued share capital will comprise 203,849,437 Ordinary Shares of £0.01 each, each carrying one voting right. The Company does not hold any Ordinary Shares in treasury.

Accordingly, following Admission, the total number of voting rights in the Company will be 203,849,437.

This figure may be used by shareholders as the denominator for the calculations by which they determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Availability of the Prospectus

A copy of the Prospectus is available on the Company's website at www.bsenterprise.com.

A copy of the Prospectus will also be submitted to the National Storage Mechanism and will be available for inspection at the FCA's National Storage Mechanism.

This announcement contains inside information for the purposes of Article 7 of Regulation 2014/596/EU which is part of domestic UK law pursuant to the Market Abuse (Amendment) (EU Exit) regulations (SI 2019/310).

Engage with the BSF Enterprise management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor website here: <https://bsenterprise.com/link/PR1d5r>

For further enquiries, please visit www.bsenterprise.com or contact:

BSF Enterprise PLC Geoff Baker - Chairman Che Connon - CEO & Director We encourage all investors to share questions on this announcement via our investor website.	
Bowsprit Partners John Treacy James Sheehan	+44 (0)203 883 4430
<i>ISIN of the Ordinary Shares is GB00BHNBDQ51. SEDOL Code is BHNBDQ5.</i>	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

PDIKVLBBQKLZBBK